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ABSTRACT (GENES CHROM CANCER=250 words) 
 
Molecular mechanisms underlying coordinated hypermethylation of multiple CpG islands in cancer 
remain unclear. In particular, expressional and other studies of methyltransferase enzymes have 
arrived at conflicting results. We focused on DNMT1 and DNMT3B, DNA methyltransferases 
responsible for (de novo) methylation, and EZH2, histone (H3K27) methyltransferase, and 
examined their roles in tumor suppressor gene (TSG) methylation patterns we have previously 
established in sporadic and familial cancers. Our investigation comprised 165 tumors, stratified by 
tissue of origin (117 colorectal and 48 endometrial carcinomas) and sporadic vs. familial disease 
(57 sporadic vs. 60 familial, mainly Lynch syndrome, colorectal carcinomas). By 
immunohistochemical evaluation, DNMT1, DNMT3B, and EZH2 proteins were expressed at 
significantly higher levels in tumor vs. normal tissues. DNMT1 and EZH2 expression were positively 
correlated and higher in microsatellite-unstable vs. microsatellite-stable tumors, whether sporadic 
or hereditary. The expression of Ki-67, a marker of cell proliferation, mirrored the same pattern. 
EZH2 expression was associated with a TSG methylator phenotype. Methylation at the promoters 
of the methyltransferase genes themselves was addressed as a possible cause behind their altered 
expression. No differential methylation between normal and tumor tissues was evident for 
DNMT1 or EZH2, whereas the analysis of DNMT3B corroborated the regulatory role of a distal 
promoter region. Our study shows that methyltransferase expression in cancer depends on the 
tissue of origin, microsatellite-instability status, cellular proliferation, and – in the case of DNMT3B 
– promoter methylation of the respective gene. Translation of methyltransferase expression into 
DNA methylation appears complex as suggested by the fact that except for EZH2, no clear 
association between methyltransferase protein expression and TSG methylation was observed. 
(262 words) 
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INTRODUCTION 
 
Cancer cells often show coordinated hypermethylation of multiple CpG islands, the CpG island 
methylator phenotype (CIMP), which can result in the silencing of hundreds of genes per cancer 
cell (Beggs et al. 2013). CIMP was originally described for colorectal carcinomas (Toyota et al. 1999) 
and subsequently shown to exist in most human cancers with patterns that are clearly non-
random and to certain extent tumor type-specific (Costello et al. 2000; Joensuu et al. 2008). While a 
consensus definition for CIMP is still lacking (this is true for non-colonic cancers in particular), 
CIMP is usually measured by multi-gene panels of methylation markers and tumor suppressor 
genes (Berg et al. 2014). Cancers with CIMP have distinct molecular and clinical features compared 
to those without CIMP (Issa 2008). 
 
Despite extensive descriptions of CIMP in cancer, the underlying molecular mechanisms remain 
elusive (McCabe et al. 2009). In search of responsible factors, alterations in the epigenetic 
machinery itself are of obvious interest especially as epigenetic modifiers are commonly affected 
by structural or expressional changes in cancer (Aumann and Abdel-Wahab 2014; Roy et al. 2014). 
DNA methyltransferase (DNMT) enzymes transfer a methyl group from S-adenosyl-L-methionine 
to cytosines in CpG nucleotides (Subramaniam et al. 2014). DNMT1 is mainly responsible for 
maintenance methylation and DNMT3A and DNMT3B for de novo methylation, although there is 
significant functional overlap (Egger et al. 2006; Hermann et al. 2004). Current evidence suggests that 
DNA methylation and chromatin repressive proteins act together to achieve epigenetic silencing of 
genes (Deb et al. 2014). In particular, Enhancer of Zeste Homologue 2 (EZH2), a component of the 
Polycomb repressive complex 2 (PRC2) and responsible for methylation of Lys27 of histone H3 
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(H3K27), has been suggested to serve as a recruitment platform for DNMTs (Vire et al. 2006). 
Polycomb-mediated H3K27 methylation may pre-mark genes for de novo methylation in cancer 
(Schlesinger et al. 2007; Widschwendter et al. 2007).  Combination treatment targeting the dual 
modification of DNA methylation and H3K27-trimethylation may constitute an efficient approach 
for cancer cell-specific epigenetic therapy (Takeshima et al. 2015).  
 
We have shown that tumor suppressor gene methylator phenotypes in familial/hereditary and 
sporadic cancers are characteristic of tumor type and family category (Joensuu et al. 2008). 
Familial/hereditary cancers can serve as tools to explore the causes and consequences of CIMP for 
the following reasons. First, epigenetic mechanisms play a prominent role in the various 
pathogenetic steps (constitutional susceptibility, tumor initiation, and tumor progression) of Lynch 
syndrome (LS) associated with hereditary defects in DNA mismatch repair (MMR) (Peltomaki 2014). 
Hypermethylation of the MMR gene MLH1, the most common susceptibility gene for LS (Thompson 
et al. 2014), connects CIMP with microsatellite instability (MSI) in sporadic cancers (Issa 2008). 
Second, tumors from non-polypotic colorectal cancer families without MMR defects (Familial 
colorectal cancer type X, FCCX) display different epigenetic phenotypes that may be distinguished 
by tumor suppressor promoter methylation (Joensuu et al. 2008) or alternatively, global 
hypomethylation (Goel et al. 2010; Pavicic et al. 2012); the latter may contribute to chromosomal 
instability in tumors (Issa 2008). While the molecular basis of FCCX is mostly unknown, the above 
observations imply a potential role for genes controlling epigenetic processes. Third, the CIMP 
profiles in familial/hereditary cancers mimic those of their sporadic counterparts (Esteller et al. 
2001; Joensuu et al. 2008), suggesting that familial cancers can be used as general CIMP models.  
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This study was designed to investigate if altered expression of DNMTs (DNMT1 and DNMT3B) or 
EZH2 might be responsible for the differential tumor suppressor gene methylation patterns 
observed in familial and sporadic tumors (Joensuu et al. 2008). Moreover, promoter methylation of 
some key epigenetic genes (DNMTs and microRNAs targeting methyltransferase genes) was 
recently implicated in the regulation of epigenetic patterns (Huidobro et al. 2012; Suzuki et al. 2013), 
encouraging us to evaluate such events as possible mechanisms behind altered methyltransferase 
expression in our sample series.   
 
MATERIALS AND METHODS 
 
Patients and samples 
This study included 165 tumor samples from colorectal adenocarcinoma or endometrial cancer 
patients, one tumor from each individual (CRC and EC, respectively; Table 1). Samples were 
divided into different categories based on the tissue, microsatellite instability (MSI) status and 
familial or sporadic background of cancer (Table 1). Familial CRC (Hereditary Non-Polyposis 
Colorectal Cancer) included DNA mismatch repair (MMR) gene mutation-positive and mutation-
negative groups (LS-CRC and FCCX, respectively). All ECs were from LS patients. 
In addition, we studied a series of endometrial samples representing different hyperplastic stages; 
37 normal endometrium (N), 11 simplex hyperplasia (SH), 9 complex hyperplasia (CH), 18 complex 
atypical hyperplasia (CAH), and 11 endometrial carcinomas from 34 LS patients (Nieminen et al. 
2009). MSI was present in 0, 18, 78, 50 and 70% of the sample groups, respectively. 
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The patients represented either a nationwide registry of hereditary CRC families (LS groups, 
hyperplasias and FCCX (Mecklin et al. 1987)) or a population-based cohort of sporadic CRCs from 
Mikkeli hospital district in Finland (Joensuu et al. 2008).  
Tissue sections for immunohistochemical (IHC) slides were cut from paraffin-embedded tissue 
blocks or tissue microarrays and DNA was extracted by a method modified from Isola et al. (1994). 
Mutation screening, MSI analysis (revised Bethesda panel: Umar et al. 2004), IHC analysis for the 
MMR proteins and part of the tumor suppressor gene (TSG) promoter methylation screening were 
performed in previous studies (Abdel-Rahman et al. 2005; Holmberg et al. 1998; Joensuu et al. 2008; 
Nieminen et al. 2009; Ollikainen et al. 2005; Renkonen et al. 2003; Schweizer et al. 2001).  
This study was approved by the institutional review board of the Helsinki University Central 
Hospital. 
 
Immunohistochemical analyses 
IHC analyses for DNMT1, DNMT3B and EZH2 were performed using mouse or rabbit primary 
antibodies and the Dako EnVisionTM+ System-HRP (DAB) detection by the manufacturer’s standard 
protocol (Agilent Technologies, Glostrup, DK). Rabbit polyclonal DNMT1 antibody (product no 
ab19905, Abcam, Cambridge, UK) was used in 1:700 dilution with antigen retrieval in EDTA pH 8.0 
buffer and with primary antibody incubation for 18-20 hrs. Mouse monoclonal DNMT3B antibody 
(product no IMG-184A, Imgenex/Novus Biologicals, Littleton, CO) was used in 1:250 dilution in 
0.01 M citrate buffer pH 6.0, and primary antibody incubation was 18-20 hrs.  Mouse monoclonal 
EZH2 antibody (product no 612667, clone 11, BD Biosciences, Franklin Lakes, NJ) was used in 1:25 
dilution in Tris-EDTA pH 9.0 with primary antibody incubation of 24 hrs. 
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Ki-67 (Dako, clone MIB-1) staining was done by Ventana/Roche’s ultraVIEW Universal DAB 
Detection Kit with RTU preparation buffer CC1 and RTU Hematoxylin II. Antibody dilution was 
1:100 and incubation time 32 min. 
To quantify nuclear expression of DNMT1, DNMT3B and EZH2, a staining index (SI) was 
determined by the product of intensity of the staining (range 0-3) multiplied by the percentage of 
stained nuclei (0=0, <10=1, 10-50=2, >50=3) similar to published studies (Collett et al. 2006; Fluge et 
al. 2009; Foulkes et al. 2003). Ki-67 expression was measured by the percentage of stained nuclei. 
 
Custom MS-MLPA for DNMT1, DNMT3B and EZH2 promoter methylation 
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay was 
designed to study DNA methylation of selected sites in DNMT1, DNMT3B and EZH2 promoter 
areas. We screened genomic sequences 5000 bp upstream from the transcription start site (TSS) 
and the downstream sequences including the first exon and intron of DNMT1, DNMT3B and EZH2 
for CpG islands. EMBOSS Cpgplot and TFSEARCH softwares were used to locate the CpG islands 
and common transcription factor binding sites. Methylation status of the CpG islands was 
determined by bisulfite sequencing with methylation-unbiased primers (Supporting Information 
Table S1) and HhaI sites from representative areas were chosen for the design of MS-MLPA probes 
(1 probe  for DNMT1, 2 for DNMT3B and 4 for EZH2, Supporting Information Table S1). Custom 
probes were added to the SALSA MLPA P300 Human DNA reference-2 probemix with FAM-labeled 
SALSA MLPA EK1 reagent kit (MRC-Holland, Amsterdam, NL) and the assays performed following 
the manufacturer’s protocol. The studied CpG sites were the following: DNMT1 +31 bp, DNMT3B -
444 and -104 bp and EZH2 -1217, -56/-87, +619 and +22770 bp from TSS (www.ensembl.org). The 
methylation dosage ratios (Dm) were calculated as described (Gylling et al. 2008). MS-MLPA results 
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were validated against bisulfite sequencing in 3 commercial normal tissue samples and 7 cancer 
cell lines by a protocol outlined in Pavicic et al. (2011). 
 
Bisulfite sequencing  
Bisulfite sequencing was performed to validate the custom MS-MLPA methylation results. We 
used altogether 10 commercial samples or cell lines to study the methylation status of DNMT1, 
DNMT3B and EZH2 promoter areas (specific sites described above). DNA bisulfite conversion was 
done by CpGenome DNA Modification Kit (Chemicon/Merck Millipore, Billerica, MA) according to 
the manufacturer’s instructions and bisulfite sequencing was performed by using HotstarTaq 
(Qiagen, Hilden, DE) with specifically designed primers amplifying both methylated and 
unmethylated DNA by manufacturer’s standard cycling protocol (for primer sequences see 
Supporting Information Table S1).  
mRNA expression microarray before and after DNA demethylating treatment 
RMA pre-processed mRNA microarray expression data, before and after DNA demethylating 
treatment, were retrieved for DNMT1, DNMT3B and EZH2 from Niskakoski et al. (2014). Expression 
data were available for RKO, HCT116 and HCT15 colon cancer cell lines. Cells were treated with 5 
µM 5-aza-2’deoxycytidine (A3656, Sigma-Aldrich, St. Louis, MO) for 96 hours and 300 nM TSA 
(trichostatin, T1952, Sigma-Aldrich) for 18 hours. The mRNA levels were studied by Affymetrix 
GeneChip Human Genome U133 Plus 2.0 Arrays. 
 
Statistical analyses 
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Statistical analyses were conducted by using PASW Statistics 18 software (SPSS Inc.). Shapiro-Wilk 
test was used to test the normality of the data. Correlations between DNMT1, DNMT3B, EZH2 and 
Ki-67 expressions and 24 tumor suppressor genes or LINE-1 methylation were tested by 
Spearman’s rank correlation for non-parametric data. Mann-Whitney U test was used to test the 
differences in expression between groups (e.g., CIMP-low/CIMP-high or Ki-67-low/Ki-67-high) and 
Wilcoxon Signed-Rank to test the differences between tumors and paired normal samples. 
Clinicopathological characteristics (location of tumor, age of diagnosis, gender, grade and stage) or 
Dm values from custom MT promoter MS-MLPA or MT targeting miRNAs MS-MLPA (Walter 2011) 
vs. protein expressions tested either with Kruskal-Wallis, Mann-Whitney U, or Spearman 
correlation analysis as appropriate. All presented P-values (sig.) are 2-tailed (P < 0.05 were 
considered significant). 
 
RESULTS 
 
In an attempt to clarify underlying causes for aberrant DNA methylation in tumors (Joensuu et al. 
2008), DNMT1, DNMT3B and EZH2 protein expression was studied by IHC in 203 samples of 
formalin-fixed paraffin-embedded colorectal or endometrial tumors or endometrial hyperplasia 
and paired normal tissues (Materials and Methods and Table 1). In addition, we used MS-MLPA to 
investigate if methyltransferase genes are regulated by promoter methylation and if specific 
methyltransferase targeting microRNAs (miR-152, miR-148a and miR-124a) show any association 
with the expression levels of the methyltransferases under study. 
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DNMT1, DNMT3B, EZH2 and Ki-67 protein expression in colorectal and endometrial tumors vs. 
normal tissues  
Examples of different staining patterns are depicted in Supporting Information Fig. S1 and Fig. S2. 
In all patient groups with CRC, DNMT1, DNMT3B and EZH2 proteins were expressed at significantly 
higher levels in tumors than in normal mucosa (Fig. 1 and Supporting Information Table S2). 
DNMT1 in FCCX-CRC constituted the only exception (with borderline significance of P = 0.067). The 
average group-specific staining indices were 2.65–5.35 for DNMT1, 6.52–8.00 for DNMT3B, and 
1.79–6.58 for EZH2 in CRC tumors and 1.13–2.56, 0–2.11, and 0–1.33 in paired normal mucosa, 
respectively. DNMT3B showed a significantly higher expression in LS-EC vs. normal endometrium, 
whereas DNMT1 and EZH2 protein expressions were relatively low in endometrial tumors and 
normal endometrium samples with no statistically significant differences (Fig. 1, Supporting 
Information Table S2). The results are shown case by case in Supporting Information Fig. S3. 
Ki-67 was investigated to address cellular proliferation. Ki-67 expression was consistently higher in 
tumor than normal tissues (Fig. 1). Statistical significance was reached in sporadic MSS-CRC and LS-
CRC groups (average staining 43.3% vs. 16.8%, P = 0.001, and 48.8% vs. 12.6%, P < 0.001, in tumors 
vs. normal tissues, respectively).   
 
Relationship between different methyltransferases and comparison of tumors from different 
patient groups  
The patterns of DNMT1 and EZH2 expression in tumors mirrored each other (Fig. 1). By Spearman 
correlation analysis, EZH2 was significantly correlated with DNMT1 expression in the combined 
groups of all CRCs (P = 0.001) and sporadic CRCs (P = 0.003).  
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To evaluate expression differences between CRC tumors representing different patient groups, in 
addition to the group averages shown in Fig. 1, box plots for expression distributions in tumors 
were established (Supporting Information Fig. S4). The expression of DNMT1 and EZH2 were 
higher in MSI than MSS tumors, whether sporadic (sporadic MSI vs. sporadic MSS) or hereditary 
(LS-CRC vs. FCCX). The difference was statistically significant between LS-CRC and FCCX for DNMT1 
(P = 0.002), and between sporadic MSI-CRC and sporadic MSS-CRC for EZH2 (P = 0.026). 
Furthermore, Ki-67 expression showed a MSI-status-dependent pattern similar to DNMT1 and 
EZH2 (Supporting Information Fig. S4).  DNMT3B revealed high levels of protein expression in all 
CRC groups and no clear group-specific patterns.  
For colorectal vs. endometrial comparisons, the four CRC subgroups were combined (“all CRC” in 
Supporting Information Table S2) and the single LS-EC group represented ECs. EZH2 and DNMT1 
were expressed at significantly higher levels in colorectal than endometrial carcinomas (mean SI 
4.20 vs. 0.89 for EZH2 and 4.34 vs. 1.19 for DNMT1 in CRC and EC, respectively; P < 0.001 for both 
comparisons, Supporting Information Table S2). A similar trend was seen already in the respective 
normal tissue samples. DNMT3B was expressed at high levels in both CRCs and ECs (mean SI 6.94 
in CRC and 6.50 in EC). 
 
Ki-67 expression vs methyltransferase expression in tumors 
We divided the tumors into two subgroups based on their Ki-67 expression values: Ki-67-high with 
expression greater than or equal to the median (47.5% of stained nuclei for CRC and 15% for EC) 
and Ki-67-low with expression lower than the median. Mann-Whitney U test was used to test 
differences in methyltransferase expression between the two subgroups (Fig. 2 upper panel, 
Supporting Information Table S3). EZH2 expression was significantly associated with the high Ki-67 
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subgroup in sporadic MSS-CRCs (SI 2.94 in Ki-67 high vs. 0.76 in Ki-67 low subgroup; P = 0.017) and 
in the combined sporadic CRCs (SI 3.95 in Ki-67 high vs. 0.88 in Ki-67 low subgroup; P = 0.001). 
However, this association was not evident in all patients (Supporting Information Fig. S2). DNMT1 
expression was associated with Ki-67-high in sporadic MSI CRCs (SI 5.65 in Ki-67 high vs. 2.00 in Ki-
67 low subgroup; P = 0.014) and LS-EC (SI 1.50 in Ki-67 high vs. 0.12 in Ki-67 low subgroup; P = 
0.030). For DNMT3B expression, stratification by Ki-67 status had little effect (Supporting 
Information Table S3).  
 
Methyltransferase expression vs aberrant TSG promoter methylation in tumors 
Tumor suppressor gene methylation status differed significantly between individual patient groups 
(P < 0.001) with sporadic MSI-CRC having clearly the highest number of methylated TSG promoters 
(mean 7.24 out of 24 genes) compared to other CRC groups (3.39–4.03; Supporting Information 
Table S2). We defined high TSG methylator phenotype (CIMP+ in Fig. 2) as at least 5 methylated 
promoters out of 24 and low TSG methylator phenotype (CIMP-) as less than 5 methylated 
promoters out of 24 (Joensuu et al. 2008). EZH2 expression was significantly associated with CIMP+ 
in sporadic MSS-CRC (average SI 3.88 in CIMP+ vs. 1.35 in CIMP- tumors; P = 0.028) and in the 
combined sporadic (MSS + MSI) group (average SI 4.62 in CIMP+ vs. 1.65 in CIMP- tumors, P = 
0.003; Fig. 2 lower panel and Supporting Information Table S3). Stratification by CIMP status did 
not reveal significant differences in DNMT1 or DNMT3B expression (Fig. 2 and Supporting 
Information Table S3).  
 
Methyltransferase expression in the endometrial hyperplasia series 
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A progressive trend from normal endometrium to SH to CH to CAH was evident for DNMT1, 
DNMT3B and EZH2 expression (Fig. 3, Supporting Information Fig. 5 and Table S2). Statistical 
significance could not be tested due to small sample sizes (see Materials and Methods). The 
results are broadly concordant with our previous findings of TSG promoter methylation in 
hyperplastic tissues with normal endometrium and SH clustering into a low-methylator group and 
CH, CAH, and EC clustering into a high-methylator group; (Nieminen et al. 2009).  
 
Possible causes behind aberrant methyltransferase expression 
To investigate if expression of the methyltransferases in question is controlled by methylation of 
their own promoters, a custom MS-MLPA assay was designed that included probes targeting the 
promoter areas of DNMT1, DNMT3B and EZH2 (Materials and Methods). Only one DNMT3B site, 
monitored by the DNMT3B probe 1, showed a statistically significant (P < 0.001) differential 
methylation between CRC tumors and normal mucosa (Table 2). This DNMT3B probe scanned the 
same distal promoter area as that described in Huidobro et al. (2012), our CpG site being located 
444 bp upstream of TSS. In individual tumors, the methylation dosage ratio (Dm) varied between 0 
and 0.46 (indicating 0–46% methylation) and in the paired normal mucosae between 0 and 0.24 
(data not shown). Among the different patient groups, the DNMT3B distal promoter showed a  
significantly higher methylation relative to normal mucosa in sporadic MSS-CRC and LS-CRC 
tumors (P = 0.010 and P = 0.033, respectively; Table 2). The highest degrees of promoter 
methylation were seen in samples from LS-CRC (up to Dm 0.46) and sporadic MSI-CRC groups (up 
to Dm 0.40).  
LS-CRC was the only patient group with some variation in DNMT3B protein expression between 
the individual tumors (Supporting Information Fig. S4). Therefore, we focused on LS-CRCs to study 
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if methylation of the distal promoter was associated with protein expression. DNMT3B expression 
was stratified into low (SI < 4) and high (SI > 4) based on the box plot in Supporting Information 
Fig. S4. Methylation of the DNMT3B distal promoter was negatively associated with protein 
expression with borderline significance (P = 0.080). The median Dm was 0.35 in DNMT3B-low 
expression 0.15 in DNMT3B-high expression group.  
Demethylation treatments of colorectal cancer cell lines, followed by array-based profiling, 
revealed a 2.4-fold increase in DNMT3B mRNA expression in HCT15 and a 1.6-fold increase in RKO 
after treatment (P < 0.05), in agreement with the results from Huidobro et al. (2012). In HCT116, 
the distal promoter was unmethylated and consequently, no treatment effect was either expected 
or seen.  
We also analyzed if methyltransferase protein expression correlated with the methylation status 
of specific miRNA loci (Pavicic et al. 2011) known to target the respective methyltransferase genes. 
MiR-152 targets DNMT1 (Braconi et al. 2010), miR-148a DNMT3B (Duursma et al. 2008) and miR-
124a(1-3) EZH2 (Zheng et al. 2012). No significant positive correlations were observed (see 
Discussion). 
 
Methyltransferase expression vs. clinical characteristics 
There was no significant correlation between the protein expression of DNMT1, DNMT3B or EZH2 
and different clinical characteristics (gender, age of diagnosis, stage, grade or location of tumor). 
This probably reflected sample size and the selective nature of the samples. 
 
DISCUSSION 
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DNMTs and EZH2 control multiple cancer-relevant biological processes, such as cell proliferation, 
DNA damage response, DNA repair, and stemness, which in turn can influence malignant 
transformation, invasion, cancer progression, and metastasis (Campbell et al. 2013; Jin and Robertson 
2013; Yamaguchi and Hung 2014). These activities may be mediated by altered DNA or histone 
methylation e.g., inactivation of genes involved in DNA damage repair by promoter methylation, 
(Jin and Robertson 2013) or be independent of methylation (several functions known, Jin and Robertson 
2013; Yamaguchi and Hung 2014). Prompted by discordant data between DNMT expression and 
CIMP in the available literature (Eads et al. 1999; Kanai et al. 2001) and the virtual lack of published 
data concerning the relationship between EZH2 expression and CIMP, we undertook an 
immunohistochemical investigation of DNMT1, DNMT3B, and EZH2 expression in CRC and EC from 
sporadic and familial cases. Consistent patterns of expression emerged, showing significant 
variation between the individual patient groups. Moreover, elevated expression of EZH2, rather 
than DNMT1 or DNMT3B, was associated with TSG methylator phenotype in tumors.  Implications 
of the findings will be discussed below.   
 
Results of DNMT expression and relationship with CIMP in cancer vary a lot in part because of 
different methodologies used to assess expression (real-time PCR analysis of mRNA vs. IHC 
analysis of protein) and CIMP (no consensus definition exists). Overexpression of one or several 
DNMTs compared to adjacent normal tissue is seen from below 10% to over 70% of various 
cancers (Etoh et al. 2004; Girault et al. 2003; Kanai et al. 2001; Nosho et al. 2009; Xiong et al. 2005). Even 
studies employing the same methodology have arrived at conflicting results. Focusing on CRC, 
Eads et al. (1999) found that mRNAs of DNMT1, DNMT3A, or DNMT3B were not upregulated when 
normalized with proliferation-associated genes, and expression showed no correlation with CIMP, 
whereas Kanai et al. (2001) reported that mRNAs of DNMT1 and DNMT3B were significantly 
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elevated after normalization with proliferation-associated markers, and overexpression of DNMT1 
was significantly associated with CIMP. Overexpression of EZH2 (typically determined by IHC and 
defined as staining indices above the median) has been reported to occur in 17% of CRC (Fluge et 
al. 2009), 18% of EC (Bachmann et al. 2006), and up to 51% of breast carcinomas (Collett et al. 2006). 
While we made no attempt to determine cut-off-based fractions of tumors overexpressing 
DNMT1, DNMT3B, or EZH2 among our CRCs and ECs, the SI values in tumor tissues significantly 
exceeded those in paired normal tissues in virtually all patient groups (Fig. 1). In studies 
mentioned above (Bachmann et al. 2006; Collett et al. 2006; Fluge et al. 2009), EZH2 was significantly 
associated with Ki-67 expression, which broadly agrees with our data (Supporting Information Fig. 
S2). None of the investigations examined CIMP. Compatible with our findings, Hoffman et al. 
(2007), who studied prostate cancer, observed elevated expression of EZH2, but not DNMT1 or 
DNMT3B, in association with increased DNA methylation (of the same TSGs we analyzed). The 
association of EZH2 expression with TSG promoter methylation is consistent with the idea that 
EZH2 is required for the establishment of DNA methylation patterns (Deb et al. 2014). 
 
Our observation of higher DNMT1 and EZH2 protein expression in MSI vs. MSS CRCs is particularly 
interesting and novel. The finding applied to both sporadic and hereditary cancers (P = 0.026 for 
EZH2 in sporadic MSI-CRC vs. sporadic MSS-CRC, and P = 0.002 for DNMT1 in LS-CRC vs. FCCX, 
Supporting Information Fig. S4). Previously, overexpression of DNMT3B protein was reported to be 
significantly associated with CIMP-high and MSI-high phenotypes in CRC (Nosho et al. 2009), 
whereas CRCs from our study showed uniformly high levels of DNMT3B expression irrespective of 
MSI status (Supporting Information Fig. S4). Mechanisms accounting for the observed associations 
between DNMT1 or EZH2 expression and MSI are unknown. Studies have found no evidence of 
physical interaction between MMR proteins and DNMTs or EZH2, although altered 
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methyltransferase expression can indirectly influence MMR gene expression (Loughery et al. 2011; 
Wang et al. 2013).  
 
Altered expression and/or function of DNMTs and EZH2 in tumors may result from several 
alternative mechanisms. These include constitutional polymorphisms (Crea et al. 2012; Shen et al. 
2002) and somatic mutations (Kanai et al. 2003; Roy et al. 2014) of the DNMT and EZH2 genes. 
Alternative splicing can influence the expression levels of DNMT3B (Veeck and Esteller 2010). We 
focused on miRNAs targeting DNMTs or EZH2 (so called “epi-miRNAs”) whose roles as 
methyltransferase regulators are well established (Suzuki et al. 2013), and promoter methylation of 
the DNMT and EZH2 genes themselves, for which little information is available (Huidobro et al. 
2012; Li et al. 2014). It has been hypothesized that inactivation of an epi-miRNA (e.g., miR-152) by 
methylation leads to increased expression of its target epigenetic gene (e.g., DNMT1), thereby 
creating a self-amplified loop (Valeri et al. 2009). We found no significant positive correlations 
between methylation of CpG islands associated with miR-152, miR-148, or miR-124 (targeting 
DNMT1, DNMT3B, and EZH2, respectively) vs. DNMT or EZH2 expression, which could reflect a 
variety of reasons, including the likely scenario that the independent effects of the miRNAs were 
not strong enough to control the expression of the respective genes alone. Evaluation of DNMT1, 
DNMT3B, and EZH2 promoters for methylation in patient specimens revealed a consistent 
difference between normal and tumor tissues for DNMT3B only (Table 2), and DNMT3B ‒ unlike 
DNMT1 and EZH2 ‒ also showed upregulation after demethylation treatment of cell lines. Our 
data as a whole supported the findings by Huidobro et al. (2012) of an area outside the CpG island 
(“distal region”) regulating DNMT3B expression.   
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The mechanistic basis of CIMP remains unsettled. The CIMP phenotype and altered 
methyltransferase expression often co-exist in tumorigenesis, sharing early appearance (Ding et al. 
2006; Ibrahim et al. 2011), tissue-specificity (Joensuu et al. 2008, this study), involvement in tumor 
progression (Ibrahim et al. 2011, this study in regard to endometrial hyperplasias), and contribution to 
the prognosis of CRC and EC (Bachmann et al. 2006; Benard et al. 2014; Fluge et al. 2009; Issa 2008). 
Such observations imply that the processes are likely to be linked, although their relationship may 
not be straightforward. In our investigation, EZH2 in particular came up through associations with 
the TSG methylator phenotype (Fig. 2) and a role in the multistep endometrial tumorigenesis (Fig. 
3). While our study was in progress, Jia N et al. (2014) reported that EZH2 overexpression stratified 
endometrial lesions into high expression (CH, CAH, and EC) and low expression groups (normal 
endometrium and SH), a division identical to that we have previously shown to apply to the 
distribution of high vs. low TSG methylator phenotypes among endometrial lesions (Nieminen et al. 
2009). Our EZH2 expression results indicated a progressively increasing trend from normal 
endometrium to SH to CH to CAH to EC (Fig. 3), but no statistical differences between types of 
lesions were obtained due to the small number of cases. Given that H3K27 methylation may pre-
mark genes for de novo methylation in cancer (Schlesinger et al. 2007; Widschwendter et al. 2007), 
EZH2 may contribute to some of the selective aspects of CIMP mentioned above. In this capacity, 
EZH2 may also constitute a promising therapeutic target that could allow for efficient anti-cancer 
treatment without affecting global methylation status and gene silencing beyond cancer cells (Deb 
et al. 2014; Roy et al. 2014; Yamaguchi and Hung 2014). 
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